Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
Bristol Myers Squibb will present oncology data across 12 oral presentations and nearly 60 disclosures at the ESMO 2026 Congress, October 23-27 in Madrid. Key late-breaking data include two Phase 3 studies of izalontamab brengitecan (iza-bren), a potential first-in-class EGFR x HER3 bispecific ADC, in EGFR-mutated NSCLC (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01), plus Phase 2 data for the BioNTech-co-developed bispecific pumitamig in metastatic NSCLC.
Key figures
- Total disclosures
- nearly 60
- Oral presentations
- 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.